CorMedix (CRMD) News
NASDAQ: CRMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
5.27+0.19 (+3.74%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRMD news summary
We found 13 recent headlines mentioning CorMedix (CRMD): 2 in the past week and 10 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, CRMD is up 3.74% at $5.27. The most recent story, "Wednesday 11/18 Insider Buying Report: CRMD, PRAA", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest CorMedix headlines
- Wednesday 11/18 Insider Buying Report: CRMD, PRAABargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their…NasdaqCRMD, PRAA
- CorMedix Inc. Reports Q3 2026 Financial Results and Details Pending Heron Therapeutics AcquisitionCorMedix Inc. reported its financial results for the third quarter ended September 30, 2026, and discussed its pending acquisition of substantially all assets of Heron Therapeutics, Inc. For the…Nasdaq
- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals(RTTNews) - This week's biotech roundup features a series of regulatory approvals across obesity, stroke prevention, oncology, and medical devices, alongside workforce reductions and cost-cutting…NasdaqAMGN, ARGX, AZN, BEAM
- CorMedix Inc. Reports Third Quarter 2026 Financial ResultsCorMedix Inc. reported its third quarter 2026 financial results, posting consolidated revenue of $54.5 million, down from $104.3 million in the third quarter of 2025. The company recorded a net loss…Nasdaq
- CorMedix (CRMD) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqCRMD, WSO.B
- CorMedix (CRMD) Reports Q3 Loss, Tops Revenue EstimatesCorMedix (CRMD) delivered earnings and revenue surprises of +55.56% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqCRMD, TECH
- Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update‒ Recently announced acquisition of assets of Heron Therapeutics –GlobeNewswire
- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioCorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.NasdaqCRMD, TGTX, HRTX, AMRX
- CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareAdds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platformGlobeNewswire
- CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026,…GlobeNewswire
- Cormedix gets FDA priority review for Rezzayo label expansionSeeking Alpha
- Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal DiseasesPARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New…GlobeNewswire
- Actinium Pharmaceuticals names former CorMedix executive as CFOSeeking Alpha